GlassScriptPhysician profile
Melissa Hull
NPI 1396181814
$5,879.57
in general payments reported to CMS, 2019-2025
29 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $1,424 · 2023: $2,327 · 2024: $789 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.87 | 2022-2025 | |
| Pfizer INC. | $829.02 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $781.32 | 2021-2025 | |
| Ucb, INC. | $409.80 | 2022-2024 | Briviact, Nayzilam, Rystiggo |
| Neurocrine Biosciences, INC. | $345.12 | 2022-2024 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $332.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.84 | 2021-2024 | Hyqvia |
| Sk Life Science, INC. | $252.07 | 2025 | |
| Biogen, INC. | $217.02 | 2021-2024 | Vumerity, Tysabri, Tysabri |
| Teva Pharmaceuticals USA, INC. | $200.97 | 2022-2025 | Austedo, Austedo Xr, Ajovy |
| Averitas Pharma INC. | $160.26 | 2023-2025 | Qutenza |
| Amgen INC. | $152.39 | 2021-2023 | Aimovig |
| Grifols USA, LLC | $142.32 | 2023 | Gamunex-C |
| Acadia Pharmaceuticals INC | $106.00 | 2022-2024 | Nuplazid |
| Amneal Pharmaceuticals LLC | $102.46 | 2022-2023 | Rytary |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $80.06 | 2025 | Vyvgart |
| Lilly USA, LLC | $72.14 | 2021-2022 | |
| Lundbeck LLC | $58.03 | 2023 | Rexulti |
| Genzyme Corporation | $46.72 | 2022 | |
| Painteq LLC | $46.50 | 2023 | Painteq |
| Avion Pharmaceuticals | $41.19 | 2022 | |
| Emd Serono, INC. | $35.10 | 2022-2024 | |
| Acorda Therapeutics, INC | $25.40 | 2024 | Inbrija |
| Sunovion Pharmaceuticals INC. | $23.36 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.05 | 2025 | Ultomiris |
| Nevro Corp. | $19.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.31 | 2021 | |
| Octapharma USA, INC. | $16.92 | 2022 | |
| Ibsa Pharma INC. | $16.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.